Bimekizumab (Bimzelx; UCB Pharma) was approved by the FDA to treat psoriatic arthritis (PsA) on September 23, 2024, based on ...

Researchers identified 3 distinct PsA phenotype clusters, emphasizing the importance of PsO severity in treatment decision making.

Arthritis is a common condition characterized by joint pain and stiffness. It’s crucial to debunk myths about its causes, age ...

Topline data were announced from two phase 3 trials evaluating deucravacitinib in adults with active psoriatic arthritis.

Diseases of the joints are known as arthritis. The term is derived from the Greek word that means exactly that: diseases of ...

Psoriasis is more than just a skin condition – it’s an autoimmune disorder that can manifest as scales, spots, or even ...